Plné znění - 19/2025 Sb.

Sdělení Ministerstva zahraničních věcí, kterým se mění a doplňují sdělení Ministerstva zahraničních věcí č. 58/2007 Sb. m. s. a č. 46/2008 Sb. m. s.

19/2025 Sb.
 

Sdělení

INFORMACE

19

XXXXXXX

Xxxxxxxxxxxx zahraničních xxxx,

xxxxxx xx xxxx x xxxxxxxx xxxxxxx Ministerstva xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
 

Ministerstvo xxxxxxxxxxxx xxxx sděluje, xx xxx 1. října 2023 xxxx generální xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx nového znění Xxxxxxx X - Xxxxxx zakázaných xxxxx x xxxxx xxxxxxx xxx xxx 2024 - Mezinárodní xxxxxxxx Xxxxxxxxxxx xxxxxx xxxxx xxxxxxx xx xxxxxx.

X xxxxx xxxxxx Přílohy X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x prezident xxxxxxxxx xxxxxxxx listinu x xxxxxxx xxxx Xxxxxxx X Českou xxxxxxxxxx.

Xxxx xxxxx Xxxxxxx X xxxxxxxxx x platnost x souladu x článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2024, xxx Xxxxxx republiku xxxxxxxxx x xxxxxxxx xxx 18. června 2024 x xxxxxxxxx Xxxxxxx X pro rok 2023, platnou od 1. xxxxx 2023, xxxxx vstoupila x xxxxxxxx xxx Xxxxxx xxxxxxxxx xxx 22. xxxxxx 2023 x xxxx xxxxxxxxx pod č. 32/2023 Sb. m. s.

Xxxxxxxx znění Přílohy X pro xxx 2024 x xxxx xxxxxxx xx českého xxxxxx se vyhlašují xxxxxxxx.
&xxxx;

Xxxxxxx:

x x. JUDr. Xxxxxx, Xx.X., XX.X., x. x.

xxxxxx ředitel xxxxx xxxxxx x xxxxxxxxxx
&xxxx;

Xxxxxxx x. 1

Xxxxxxx xxxxxxxxxxx xxxxxxx xx xxxxxxx jazyka

Úvod

Seznam xxxxxxxxxx xxxxx a xxxxx xxxxxxx je xxxxxxx Xxxxxxxxxxx standard x xxxxx Xxxxxxxxx antidopingového xxxxxxxx.

Xxxxxx xx xxxxxxxxxx xxxxxxxxxxxx po xxxxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx (XXXX). Xxxxxx xx xxxxxx xx 1. xxxxx 2024.

Xxxxxxxxx xxxx Xxxxxxx zakázaných xxxxx x xxxxx bude xxxxxxxxx XXXX x xxxx xxxxxxxxxx v xxxxxxxxxx x xxxxxxxxxxxxx. X xxxxxxx xxxxxxxxxxx xxxxxxxxxxxxx xxxx anglickým x xxxxxxxxxxxx xxxxxx xxxxxxxxx xxxxx v xxxxxxxxxx.

Xxxx jsou xxxxxxx xxxxxxx xxxxx xxxxxxxxx x tomto Xxxxxxx xxxxxxxxxx xxxxx a xxxxx.

Xxxxxxxx Xxx xxxxxxx

Xxxxx XXXX pro xxxx xxxxx neschválila jiné xxxxxx, xx xxxxxx Xxx xxxxxxx x xxxxxx xxxxxxx začínajícím xxxxx xxxx půlnocí (xx 23:59 xxxxx) x xxx xxxxxxxxxxxxx Xxxxxxx, xxxxx se xx Sportovec zúčastnit, xx xx konce Xxxxxxx x procesu xxxxxx Xxxxxx.

Xxxxxxxx xxxxx

Xx xxxxxxx, xx xxxx xxxxx xxxx metoda xx xxxxxxxx Při xxxxxxx x Mimo xxxxxx, xxx xx xxxxxxxxxx v Xxxxxx.

Xxxxxxxxxx x Xxxxxxxxxxxx

Xxxxx článku 4.2.2 Světového xxxxxxxxxxxxxxx Xxxxxx „xxx xxxxx xxxxxxxx xxxxxx 10 xxxxx xxxxxxx Xxxxxxxx xxxxx Xxxxxxxxxxxx látkami, x xxxxxxxx xxxx xxxxxxxxxx v Xxxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx. Xxxxx Xxxxxxxx xxxxxx xxxxxx Xxxxxxxxxxx xxxxxxx, xxxxx xxxx x Xxxxxxx xxxxxxxxx označena jako Xxxxxxxxxx xxxxxx.“ Xxxxx xxxxxxxxx x článku „Xxxxxxxxxx xxxxx a Xxxxxxxxxx metody xxxxxxx x xxxxxx 4.2.2 xx xxxxxx být xxxxxx xxxxxxxx xxxxxxxxxx xx xxxx xxxxxxxx xxxx xxxx xxxxxxxxxx xxx xxxx dopingové xxxxx xxxx xxxxxx. Xxx spíše x xxxxx a xxxxxx, xxxxx Sportovec xxxxxxxxxxxxx xxxx xxxx xxxxxx x xxxxxx účelu xxx ke xxxxxxxx xxxxxxxxxxx xxxxxx.“

Xxxxxxxx xxxxx

Xxxxx xxxxxx 4.2.3 Kodexu xxxx Návykové xxxxx xxxxxxxxxx xxxx xxxxx, xxxxx xxxx xxxx xxxxxx xxxxxxxx z xxxxxx xxxxxx xxxxxxx xxxxxxxxxx xx společnosti xxxx xxxxx xxxxxx. Xxxx Xxxxxxxx látky xxxx označovány xxxx xxxxx: kokain, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (MDMA/„extáze“), xxxxxxxxxxxxxxxxxxx (XXX).

X0 XXXXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX I XXXX XXXXXX)

Xxxxxxx zakázané xxxxx x xxxx třídě xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxxx xxxxxxxxxxxxxx xxxxx, xx xxxxxx xx nevztahuje xxxxx x následujících xxxxxx Xxxxxxx x xxxxx xxxx x xxxxxxxx xxxx schválena xxxxxx xxxxxxx zdravotnickým xxxxxxxxxx xxxxxxx pro xxxxxxx xxxxxxx x xxxx (např. léčiva x xxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx xxxx xxxxxxx vývoj byl xxxxxxx, xxxxxxxxxx xxxxx, xxxxx schválené xxxxx xxx xxxxxxxxxxx použití), xx xxxxxxxx xxxxx.

Xxxx xxxxx xxxxxxxx xxxxx xxxxxxx xxxxx, mimo xxxx XXX-157, 2,4-xxxxxxxxxxxx (XXX) x aktivátory xxxxxxxxx (xxxx. Xxxxxxxxxxx x Xxxxxxxxxx).

X1 ANABOLICKÉ XXXXX

XXXXXXXX STÁLE (XXX XXXXXXX X XXXX XXXXXX)

Xxxxxxx zakázané xxxxx x xxxx xxxxx xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxx xxxxx xxxx zakázány.

S1.1. XXXXXXXXXX XXXXXXXXXX XXXXXXXX (XXX)

Xxx exogenním xxxxxx, xxxx xxxx xxxxxx:

•	1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-diol)		•	formebolon
•	1-androstenedion (5ɑ-xxxxxxx-1-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxx (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx)
•	1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxx
•	1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx)		&xxxx;•	xxxxxxxxxx
•	1-xxxxxxxxxxx (17ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-3-xx)		&xxxx;•	xxxxxxxxxx
•	4-xxxxxxxxxxxxxx (xxxxxxx-4-xx-3ß, 17ß-xxxx)		&xxxx;•	xxxxxxxxxxx (17ß-hydroxy-17ɑ-methylandrosta-1,4-dien-3-on)
•	4-hydroxytestosteron(4,17ß-dihydroxyandrost-4-en-3-on)		•	metenolon
•	5-androstenedion (xxxxxxx-5-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx
•	7ɑ-xxxxxxx-XXXX		&xxxx;•	xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx)
•	7ß-xxxxxxx-XXXX		&xxxx;•	xxxxx-1-xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxx-5ɑ-xxxxxxx-1-xx-3-xx)
•	7-xxxx-XXXX		&xxxx;•	xxxxxxxxxxxxxx
•	11ß-xxxxx-19-xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx (17β-hydroxy-17α-metylestra-4,9-dien-3-on)
•	17ɑ-methylepithiostanol (xxxxxxx)		&xxxx;•	xxxxxxxxxxxxxxxxxxx (17ß-hydroxy-17ɑ-metylestr-4-en-3-on)
•	19-norandrostenediol (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxxxxxxxx
•	19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx)		&xxxx;•	xxxxxxxxxx (metyltrienolon, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (5ɑ-dihydrotestosteron, 17ß-hydroxy-5ɑ-androstan-3-on)		•	nandrolon (19-xxxxxxxxxxxxxx)
•	xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxxxxx (androst-4-en-3,17-dion)		•	norklostebol (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx)
•	xxxxxxxxxx		&xxxx;•	xxxxxxxxxxxxx
•	xxxxxxxx		&xxxx;•	xxxxxxxx
•	xxxxxxx (androsta-1,4-dien-3,17-dion)		•	oxandrolon
•	calusteron		•	oxymesteron
•	klostebol		•	oxymetolon
•	danazol ([1,2]xxxxxxx[4’,5’:2,3]xxxxxx-4-xx- 20-xx-17ɑ-xx)		&xxxx;•	xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX, 3β-xxxxxxxxxxxxxx-5-xx-17-xx)
•	xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx)		&xxxx;•	xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx)
•	xxxxxxxxxxxxxxxxxxxxxx (17ɑ-methyl-5ɑ-androst-2-en-17ß-ol x 17ɑ-xxxxx-5ɑ- androst-3-en-17ß- xx)		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx)		&xxxx;•	xxxxxxxxxx
•	xxxxxxxxxxx		&xxxx;•	xxxxxxxxx
•	xxxxxxxxxxxxxx (3β-xxxxxxx-5α-xxxxxxxxx-17-xx)		&xxxx;•	xxxxxxxxxxx
•	xxx-xxxxxxxxxxxxxxxxxx (17β-hydroxy-5β-androstan-3-on)		•	tetrahydrogestrinon (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxx
•	xxxxxxxxxxxx (19-xxxxxxxxx-4-xx-17α-xx)		&xxxx;•	xxxxxxxxx (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx)
•	xxxxxxxxxxxxxx		&xxxx;•	xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, XXXX)

x xxxxx xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx biologickými účinky.

S1.2. XXXXXXX ANABOLICKÉ XXXXX

Xxxx xxxx xxxxxx:

Xxxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx, selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx [SARM, xxxx. andarin, xxxxxxxxx (xxxxxxx), XXX-4033 (xxxxxxxxx), XXX140, X-23 x XX-11], xxxxxxx x xxxxxxxxxx.

X2 XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X XXXXXXXX

XXXXXXXX XXXXX (PŘI XXXXXXX X MIMO XXXXXX)

Xxxxxxx xxxxxxxx xxxxx v xxxx třídě xxxx Xxxxxxxxxxxx látky.

Následující látky x xxxxx látky x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo podobnými xxxxxxxxxxxx xxxxxx xxxx xxxxxxxx.

X2.1. XXXXXXXXXXXXX (XXX) X LÁTKY XXXXXXXXXXX XXXXXXXXXXX

Xxxx jiné xxxxxx:

X2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx receptorů, xxxx. xxxxxxxxxxxx (dEPO); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx xx EPO, [xxxx. XXX-Xx, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; XXX- xxxxxxxxx xxxxxxxxxx x xxxxxx xxxxxxxxxx, xxxx. XXXX-530, xxxxxxxxxxx.

X2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx vyvolávajícího xxxxxxx (XXX), xxxx. xxxxxx; daprodustat (GSK1278863); XXX2; xxxxxxxxxx (XXX 85-3934); roxadustat (FG-4592); xxxxxxxxxx (XXX-6548); xxxxx.

X2.1.3 Xxxxxxxxxx XXXX, např. X-11706.

X2.1.4 Inhibitory signalizace xxxxxxxxxxxxxxxx xxxxxxxxx faktoru xxxx (TGF-β), xxxx. xxxxxxxxxxxx; sotatercept.

S2.1.5 Agonisté xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. xxxxxx XXX; xxxxxxxxxxxxx XXX (XXXX).

X2.2. XXXXXXXXX XXXXXXX X XXXXXX XXXXXXXXXX XXXXXXX

X2.2.1 Xxxxxxx xxxxxxxxxxx testosteron x xxxx, mimo xxxx včetně:

• xxxxxxxx xxxxxxxxxxxx (XX),

• luteinizační xxxxxx (XX),

• hormon xxxxxxxxxx xxxxxxxxxxxx (XxXX, xxxxxxxxxxx) x xxxx xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, leuprorelin, nafarelin x triptorelin),

 • xxxxxxxxxx x jeho xxxxxxxxxxx xxxxxxx.

X2.2.2 Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx xxxxxxx, xxxx. xxxxxxxxxxxx a xxxxxxxxxxxxx.

X2.2.3 Růstový hormon (XX), xxxx xxxxxxx x xxxxxxxxx, xxxx xxxx xxxxxx:

• xxxxxxx xxxxxxxxx hormonu, např. xxxxxxxxxxxxxxxxx, xxxxxxxxxxx a xxxxxxxxxx,

• fragmenty růstového xxxxxxx, xxxx. XXX-9604 x xXX 176–191.

X2.2.4 Xxxxxxx uvolňující xxxxxxx xxxxxx, mimo xxxx xxxxxx:

• xxxxxx xxxxxxxxxx xxxxxxx xxxxxx (GHRH) x jeho analogy, xxxx. XXX-1293, CJC-1295, xxxxxxxxxx x xxxxxxxxxxx,

• xxxxxxxxxxx růstového xxxxxxx (XXX) a xxxxxx xxxxxxxx [např. anamorelin, xxxxxxxxxxxx, xxxxxxxxxx (XX-677), xxxxxxxxxx, lenomorelin (xxxxxxx), xxxxxxxxxxx x tabimorelin],

• xxxxxxx uvolňující XX (XXXX) [xxxx. xxxxxxxxxxxx, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (xxxxxxxxxxx), GHRP-3, XXXX-4, XXXX-5 x XXXX-6].

X2.3. XXXXXXX XXXXXXX X XXXXXXXXXX XXXXXXXXX XXXXXXX

Xxxx xxxx xxxxxx:

• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)

• xxxxxxxxxxxx xxxxxxx xxxxxx (HGF)

• xxxxxxx xxxxxx 1 xxxxxxx xxxxxxxx (XXX-1, xxxxxxxxxx) x xxxx xxxxxxx

• xxxxxxxxxx růstové xxxxxxx (XXX)

• xxxxxxx xxxxxx xxxxxxxx x xxxxxxxx xxxxxxxx (PDGF)

• xxxxxxxx-β4 x jeho xxxxxxxx, xxxx. XX-500

• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx faktor (XXXX)

x xxxxx xxxxxxx xxxxxxx xxxx modulátory xxxxxxxxx xxxxxxx ovlivňující syntézu/degradaci xxxxxxxx xx svalech, xxxxxxxx nebo xxxxxx, xxxxxxxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.

X3 XXXX-2 XXXXXXXX

XXXXXXXX XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)

Všechny xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.

Xxxxxxx selektivní x neselektivní xxxx-2 xxxxxxxx včetně všech xxxxxxxxx xxxxxxx jsou xxxxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

XXXXXXX

• Xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 1600 mikrogramů xx 24 xxxxx x oddělených xxxxxxx, xxxxxxxxxxxxxxxx 600 mikrogramů xxxxx 8 xxxxx xx xxxxxxxxx xxxxx;

• xxxxxxxxx formoterol: maximálně xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;

• inhalační salmeterol: xxxxxxxxx 200 mikrogramů xx 24 hodin;

• xxxxxxxxx vilanterol: xxxxxxxxx 25 xxxxxxxxxx xx 24 xxxxx.

XXXXXXXX

Xxxxxxxxxx salbutamolu x moči v xxxxxxxx vyšším než 1000 ng/ml xxxx xxxxxxxxxxx x xxxxxxxx xxxxxx xxx 40 xx/xx xxxxxxxxxx terapeutickému xxxxxxx xxxxx a xxxx xxxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), pokud Xxxxxxxxx xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, že abnormální xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx xxxxx (xxxxxxxxx) xx xx xxxx xxxxxxx xxxxxxxxx xxxxx.

X4 XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX

XXXXXXXX STÁLE (XXX XXXXXXX I XXXX XXXXXX)

Xxxxxxxx xxxxx xx xxxxxxx X4.1 x X4.2 xxxx Xxxxxxxxxx xxxxx.

Xxxxx zařazené xx xxxx S4.3 x X4.4 xxxx Xxxxxxxxxxxx xxxxx.

Xxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.

X4.1. XXXXXXXXXX XXXXXXXX

Xxxx xxxx xxxxxx:

•	2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx)		•	xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx)
•	2-xxxxxxxxxxx (5ɑ-androst-2-en-17-on)		•	androsta-3,5-dien-7,17-dion (xxxxxxxxx)
•	3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx)		•	xxxxxxxxx
•	3-xxxxxxxxxxx (5ɑ-androst-3-en-17-on)		•	formestan
•	4-androsten-3,6,17 xxxxx (6-xxx)		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx

X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX X SELEKTIVNÍ XXXXXXXXXX XXXXXXXXXXXXX RECEPTORŮ (XXXXX)]

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx (xxxxxxxxxxxxx)
•	xxxxxxxxx		•	xxxxxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx

X4.3. XXXXX XXXXXXXXXXX XXXXXXXX XXXXXXXXX AKTIVINU XXX

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxx X		•	xxxxxxxxxx xxxxxxxxxx, např.:
•	konkurenty xxxxxxxxx xxxxxxxx XXX, xxxx.:			- xxxxx xxxxxxxxx xxxx xxxxxx xxxxxxx xxxxxxxxxx
	- xxxxxxx xxxxxxxxx xxxxxxxx (xxxx. XXX-031)			- proteiny xxxxxx myostatin (např. xxxxxxxxxxx, propeptid xxxxxxxxxx)
•	xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxxx XXX (např. xxxxxxxxxx)			- xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx xxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxx zumab, xxxxxxxxxxxxx, xxxxxxxxxx)

X4.4. XXXXXXXXXXX XXXXXXXXXX

X4.4.1 aktivátory AMP-aktivované xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, agonisté xxxxxxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx xxxxx (PPARδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) xxxxxxxx xxxxxx (XX1516, GW501516) x agonisté Xxx-xxxɑ , např. XX9009, XX9011

X4.4.2 xxxxxxxx a xxxxxxxx xxxxxxxx

X4.4.3 xxxxxxxxx

X4.4.4 xxxxxxxxxxxx

X5 DIURETIKA X XXXXXXXXX XXXXX

XXXXXXXX XXXXX (XXX XXXXXXX I XXXX XXXXXX)

Xxxxxxx xxxxxxxx xxxxx v xxxx xxxxx xxxx Specifické xxxxx.

Xxxxxxx xxxxxxxxx x xxxxxxxxx xxxxx, xxxxxx xxxxx optických xxxxxxx, xxxx. x- x x-, xxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

•&xxxx; Xxxxxxxxx, xxxx xxxx.:

xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; xxxxxxxx; xxxxxxxxxxxx; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; metolazon; xxxxxxxxxxxxx; xxxxxxxx, xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx x hydrochlorothiazid; xxxxxxxxx; triamteren;

• Vaptany, xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx;

• Xxxxxxxxxxx xxxxxxxxx xxxxxxxx intravenózně, např.:

albumin, xxxxxxx, xxxxxxxxxxx xxxxx, xxxxxxxx;

• Xxxxxxxxxxx;

• Xxxxxxxxxx;

x xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.

XXXXXXX

• xxxxxxxxxxx; pamabrom; x xxxxxxx xxxxxxxxxxxxxx xxxxxxxx inhibitorů xxxxxxxxxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxxx);

• xxxxxxx xxxxxx felypresinu x zubní xxxxxxxxx.

XXXXXXXX

Xxxxx xxxxxxxxxxx množství xxxxx xx xxxxxxxxxx prahovým xxxxxxx: u xxxxxxxxxxx, xxxxxxxxxxx, xxxxxx, efedrinu, xxxxxxxxxxxxx a pseudoefedrinu xx Vzorku Xxxxxxxxx xxxxxxxx xxxx xxxxxxxx Xxx Xxxxxxx xx xxxxxxx x xxxxxxxxxx xxxx xxxxx maskovací xxxxxx (kromě xxxxxxxxx xxxxxx podání xxxxxxxxxx xxxxxxxxxxxxxx nebo lokálního xxxxxx felypresinu v xxxxxxxx anestezii), bude xxxxxxxxx za Xxxxxxxxx xxxxxxxxxxx nález (AAF), xxxxx Xxxxxxxxx nemá xxxxxxxxxx Terapeutickou výjimku (XX) na xxxx xxxxx xxxxx x xx, která již xxxx xxxxxxx xx xxxxxxxxxx nebo xxxxx xxxxxxxxx xxxxx.

XXXXXXXX XXXXXX

XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX SOUTĚŽ)

Všechny xxxxxxxx xxxxxx x xxxx třídě jsou Xxxxxxxxxxxx x výjimkou xxxxx x X2.2, xxx xxxx Xxxxxxxxxx xxxxxx.

X1. XXXXXXXXXX X XXXX X XXXXXXXX XXXXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X1.1. Xxxxxx nebo opětovné xxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, xxxxxxxxx (xxxxxxxxx) xxxx xxxxxxxxxxx xxxx xxxx produktů x xxxxxxxxx krvinek xxxxxxxxxxx xxxxxx do xxxxxxxxx xxxxxxx s xxxxxxxx xxxxxxxx xxxxxx xxxx xxxxxx xxxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxxxxxx xxxxxxxxx x xxxxxxxxxxxxx odběrovém xxxxxx.

X1.2. Xxxxx xxxxxxxxx xxxxxx, xxxxxxx nebo xxxxxxx xxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx, xxxx. xxxxxx xxxxxxxx xx xxxx hemoglobinu a xxxxxxxxxxxxxxxx hemoglobinové xxxxxxxx, x výjimkou xxxxxxxxxxx xxxxxxx inhalací.

M1.3. Xxxxxxxxx xxxxx xxxxxxxxxxxxxxx xxxxxxxxxx x xxxx xxxx x krevními xxxxxxxxxxxx xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.

X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX

Xxxxxxxx xx xxxxxxxxxxx:

X2.1. Podvádění xxxx Xxxxx o xxxxxx xx xxxxxx xxxxxxx xxxxxxxxx x platnost Xxxxxx odebraných xxx Xxxxxxxxx xxxxxxxx.

Xxxx xxxx xxxxxx:

Xxxxxx x/xxxx úprava Xxxxxx, xxxx. xxxxxxxx xxxxxxx xx Vzorku.

M2.2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx xxxx xxx xxxxxx 100 xx xx 12 xxxxx xxxxx infuzí xxxxxxxxx xxxxxxxxx x xxxxxxx xxxxxxxxxxxx xxxxxxxx, chirurgických xxxxxxx xxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxx.

X3. XXXXXX X XXXXXXX DOPING

Z xxxxxx potencionálního xxxxxxx xxxxxxxxxxx výkonu je xxxxxxxx následující:

M3.1. Použití xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx, xxxxx xxxxx změnit sekvence xxxxxx x/xxxx exprese xxxx xxxxxxxxxx mechanismem. Xx mimo xxxx xxxxxxxx xxxxxxxxxxx úprav xxxx, umlčování genů x technologie xxxxxxx xxxx.

X3.2. Použití xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxxxx xxxxx.

X6 STIMULANCIA

ZAKÁZANÉ PŘI XXXXXXX

Xxxxxxx zakázané xxxxx x xxxx třídě xxxx Specifické xxxxx x xxxxxxxx xxxxx xxxxxxxxx x X6.X, xxx xxxx Nespecifické xxxxx.

Xxxxxxxx látky x xxxx xxxxx: xxxxxx x xxxxxxxxxxxxxxxxxxxxxxxx (MDMA/„extáze“)

Všechna xxxxxxxxxxx, včetně všech xxxxxxxxx izomerů, např. x- x x-, xxxx xxxxxxxx.

Xxxxxxxxxxx zahrnují:

S6.A: XXXXXXXXXXXX XXXXXXXXXXX

•	xxxxxxxxx		•	xxxxxxxxxxxx [4-xxxxxxxxxxxxxx (xxxxxxxx)]
•	xxxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxxxxxxxxx		•	xxxxxxxxxxxx(x-)
•	xxxxxxxxx		•	x-xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxx		•	xxxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx
•	xxxxxxxxxxx

Xxxxxxxxx, který není xxxxxxxx xxxxxx x xxxxx xxxxxx, xx Xxxxxxxxxxx xxxxxx.

X6.X: XXXXXXXXXX XXXXXXXXXXX

Xxxx xxxx včetně:

•	2-fenylpropan-1-amin (ß-xxxxxxxxxxxxxx-xxxx, XXXXX)		•	xxxxxxxxxxx		•	xxxxxxxxx
•	3-xxxxxxxxxx-2-xxxx (1,2-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxxx		•	xxxxxxxxx (xxxxxxxxxxxxx)
•	4-xxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxx
•	4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, xxxxxxxxxxxxxx)		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	4-xxxxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxxxx)		•	xxxxxxxxxx (xxxxxxxxx)		•	xxxxxxxxxxx x xxxx xxxxxxxx
•	5-xxxxxxxxxx-2-xxxx (1,4-dimetylamylamin, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX)		•	xxxxxxxxxxxxxxxx (parahydroxyamfetamin)		•	fenmetrazin
•	benzfetamin		•	isomethepten		•	fenprometamin
•	katin1)		•	levmetamfetamin		•	propylhexedrin
•	katinon x xxxx analogy, xxxx. xxxxxxxx, xxxxxxxx x ɑ-xxxxxxxxxxxxxxxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxxxxxx2)
•	xxxxxxxxxxxxxx (dimetylamfetamin)		•	metylendioxymetamfetamin		•	selegilin
•	efedrin3)		•	metylefedrin3)		•	sibutramin
•	epinefrin (xxxxxxxxx)4)		•	xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- yl)acetát]		•	solriamfetol
•	etamivan		•	metylfenidát		•	strychnin
•	etylfenidát		•	niketamid		•	tenamfetamin (xxxxxxxxxxxxxxxxxxxxx)
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxx (1,5-xxxxxxxxxxxxxxxx)

x další xxxxx x xxxxxxxx xxxxxxxxx xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx xxxxxx

XXXXXXX

• xxxxxxxx;

• xxxxxxxx xxxxxxxxxxx x xxxxxxx xxxxxx xxxxxxx, xxxxxxx, xxxxxx nebo xxxxxx xxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, oxymetazolin, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx) x stimulancia zařazená xx Xxxxxxxxxxxxxx programu 2024⁵⁾.

X7 NARKOTIKA

ZAKÁZANÉ XXX XXXXXXX

Xxxxxxx zakázané xxxxx x této třídě xxxx Xxxxxxxxxx xxxxx.

Xxxxxxxx xxxxx v xxxx xxxxx: xxxxxxxxx (xxxxxx)

Xxxxxxxxxxx xxxxxxxxx, včetně jejich xxxxxxxxxx všech xxxxxxxxx xxxxxxx, xxxx. d- x x, xxxx xxxxxxxx.

•	xxxxxxxxxxx		•	xxxxxxxx a xxxx xxxxxxxx		•	xxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx
•	xxxxxxxxx (heroin)		•	metadon		•	oxykodon		•	tramadol
						•	oxymorfon

S8 XXXXXXXXXXX

XXXXXXXX XXX SOUTĚŽI

Všechny zakázané xxxxx x této xxxxx jsou Specifické xxxxx. Xxxxxxxx látky x xxxx xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)

Xxxxxxx xxxxxxxx x syntetické xxxxxxxxxxx xxxx xxxxxxxx, např.

• x xxxxxx (hašiš, xxxxxxxxx) a xxxxxxxxx xxxxxxxxxx

• přírodní x xxxxxxxxxx xxxxxxxxxxxxxxxxxxxxx (XXX)

• xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxx THC

VÝJIMKY

• xxxxxxxxxx

X9 XXXXXXXXXXXXXXX

XXXXXXXX PŘI SOUTĚŽI

Všechny xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx látky.

Všechny glukokortikoidy xxxx zakázány, xxxxx xxxx podávány jakoukoliv xxxxxxxx, xxxxxxxxx [včetně xxxxxxxxxx (např. bukální, xxxxxxxxxx, sublingvální)] nebo xxxxxxxx xxxxxx.

Xxxx xxxx xxxxxx:

•	xxxxxxxxxxxx		•	xxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxxx xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxxxxx
•	xxxxxxxxxxx		•	xxxxxxxxxxxxxxxx

XXXXXXXX

• Xxxx xxxxxxx xxxxxx (včetně xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, dermálního, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, xxxxxx x xxxxxxxxxxxx) xxxxxx xxxxxxxx, xxxxx xx xxxxxxxxx x xxxxx xxxxxxxx xxxxxxxxxxxx xxxxx x xxxxxxxxxxxxxx xxxxxxxx.

X1 BETA-BLOKÁTORY

ZAKÁZANÉ X URČITÝCH SPORTECH

Všechny xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.

Xxxx-xxxxxxxxx jsou xxxxxxxx pouze v xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx a xxx xx to xxxxxxxx xxxxxxxx (*) x Xxxx xxxxxx.

• xxxxxxxxxxx (XX)*

• xxxxxxxx/xxxxxxxxxxxx (XXX) – xxxxx na xxxxxx, xxxxxxxxxxx skoky / U-rampa x xxxxxxxxx U-rampa / xxx air

• automobilový xxxxx (XXX)

• xxxxxxxx xxxxxx (XXXX)* x xxxxxxxxxxxx xxxxxxx potápění, xxxx harpunou x xxxxxxx xx xxxx

• xxxxxxxx (všechny xxxxxxxxxx) (XXXX)

• xxxxx (WDF)

• xxxx (XXX)

• minigolf (XXX)

• xxxxxxx (ISSF, XXX)*

* xxxxxxxx xxxx Xxxx xxxxxx

Xxxx xxxx xxxxxx:

•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxx
•	xxxxxxxxxx		•	xxxxxxxxx		•	xxxxxxxxxxxx		•	xxxxxxxx
•	xxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxxxxxx
•	xxxxxxxxx		•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxx
•	xxxxxxxxxx		•	xxxxxxx		•	xxxxxxxxx		•	xxxxxxx

Xxxxxxx x. 2

Xxxxx xxxxxxxxxxx smlouvy x xxxxxxxxx jazyce
 

¹⁾ xxxxx (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: xx xxxxxxxx xxxxx xxx koncentraci x moči xxxxx xxx 5 xxxxxxxxxx x 1 xx.

²⁾ xxxxxxxxxxxxx: zakázaný xxxxx xxx koncentraci x xxxx xxxxx xxx 150 xxxxxxxxxx x 1 xx.

³⁾ xxxxxxx x xxxxxxxxxxxx: zakázány xxx koncentraci x xxxx vyšší než 10 mikrogramů x 1 xx.

⁴⁾ xxxxxxxxx (xxxxxxxxx): není xxxxxxxx xxxxxxx podávání, xxxx. xxxxx, oční, xxxx xxxxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx.

⁵⁾ xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx a xxxxxxxx: tyto látky xxxx xxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx 2024 x xxxxxx xxxxxxxxxx xx Zakázané xxxxx.

Xxxxxxxxx

Xxxxxx xxxxxxx x. 19/2025 Sb. xxxxx xxxxxxxxx xxxx 28.1.2024.

Znění xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx se xxxx xxxxxx xxxxxxxxx xxxxx shora xxxxxxxxx xxxxxxxx předpisu